{"id":4915,"date":"2023-08-10T17:50:33","date_gmt":"2023-08-10T17:50:33","guid":{"rendered":"https:\/\/ctm.u-bourgogne.fr\/?p=4915"},"modified":"2024-01-26T18:00:37","modified_gmt":"2024-01-26T18:00:37","slug":"first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial","status":"publish","type":"post","link":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/","title":{"rendered":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial. Nat Med. 2023 Aug;29(8):2087-2098. doi: <a href=\"https:\/\/www.nature.com\/articles\/s41591-023-02497-z\" title=\"\">10.1038\/s41591-023-02497-z<\/a>. Epub 2023 Aug 10. PMID: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37563240\/\" title=\"\">37563240<\/a>; PMCID: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10427431\/\" title=\"\">PMC10427431<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37563240\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/37563240\/<\/a><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"720\" height=\"816\" src=\"https:\/\/ctm.u-bourgogne.fr\/wp-content\/uploads\/2024\/01\/Image2.png\" alt=\"\" class=\"wp-image-4916\" srcset=\"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/01\/Image2.png 720w, https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/01\/Image2-265x300.png 265w\" sizes=\"(max-width: 720px) 100vw, 720px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with &#8230; <a title=\"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial\" class=\"read-more\" href=\"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/\" aria-label=\"En savoir plus sur First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial\">Lire la suite<\/a><\/p>\n","protected":false},"author":23,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[3],"tags":[],"class_list":["post-4915","post","type-post","status-publish","format-standard","hentry","category-publication"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Francois Hermetet\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"CTM -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial - CTM\" \/>\n\t\t<meta property=\"og:description\" content=\"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-08-10T17:50:33+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2024-01-26T18:00:37+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial - CTM\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#blogposting\",\"name\":\"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\\\/2 trial - CTM\",\"headline\":\"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\\\/2 trial\",\"author\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ctm.u-bourgogne.fr\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Image2.png\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#articleImage\"},\"datePublished\":\"2023-08-10T17:50:33+00:00\",\"dateModified\":\"2024-01-26T18:00:37+00:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#webpage\"},\"articleSection\":\"Publication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ctm.ube.fr\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/category\\\/publication\\\/#listItem\",\"name\":\"Publication\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/category\\\/publication\\\/#listItem\",\"position\":2,\"name\":\"Publication\",\"item\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/category\\\/publication\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#listItem\",\"name\":\"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\\\/2 trial\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#listItem\",\"position\":3,\"name\":\"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\\\/2 trial\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/category\\\/publication\\\/#listItem\",\"name\":\"Publication\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#organization\",\"name\":\"CTM\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/CTM-LOGO-350_70.jpg\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#organizationLogo\",\"width\":350,\"height\":70},\"image\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/#author\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/\",\"name\":\"Francois Hermetet\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8d660d5bc961dd55ff293be175456994b87cd31966fb5a061dfb4ad2af59b627?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Francois Hermetet\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#webpage\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/\",\"name\":\"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\\\/2 trial - CTM\",\"description\":\"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/08\\\/10\\\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/#author\"},\"datePublished\":\"2023-08-10T17:50:33+00:00\",\"dateModified\":\"2024-01-26T18:00:37+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#website\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/\",\"name\":\"CTM\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial - CTM","description":"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with","canonical_url":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#blogposting","name":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial - CTM","headline":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial","author":{"@id":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/#author"},"publisher":{"@id":"https:\/\/ctm.ube.fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/ctm.u-bourgogne.fr\/wp-content\/uploads\/2024\/01\/Image2.png","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#articleImage"},"datePublished":"2023-08-10T17:50:33+00:00","dateModified":"2024-01-26T18:00:37+00:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#webpage"},"isPartOf":{"@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#webpage"},"articleSection":"Publication"},{"@type":"BreadcrumbList","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr#listItem","position":1,"name":"Home","item":"https:\/\/ctm.ube.fr","nextItem":{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/#listItem","name":"Publication"}},{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/#listItem","position":2,"name":"Publication","item":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/","nextItem":{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#listItem","name":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial"},"previousItem":{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#listItem","position":3,"name":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial","previousItem":{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/#listItem","name":"Publication"}}]},{"@type":"Organization","@id":"https:\/\/ctm.ube.fr\/#organization","name":"CTM","url":"https:\/\/ctm.ube.fr\/","logo":{"@type":"ImageObject","url":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#organizationLogo","width":350,"height":70},"image":{"@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/#author","url":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/","name":"Francois Hermetet","image":{"@type":"ImageObject","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/8d660d5bc961dd55ff293be175456994b87cd31966fb5a061dfb4ad2af59b627?s=96&d=mm&r=g","width":96,"height":96,"caption":"Francois Hermetet"}},{"@type":"WebPage","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#webpage","url":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/","name":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial - CTM","description":"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/ctm.ube.fr\/#website"},"breadcrumb":{"@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/#breadcrumblist"},"author":{"@id":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/#author"},"creator":{"@id":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/#author"},"datePublished":"2023-08-10T17:50:33+00:00","dateModified":"2024-01-26T18:00:37+00:00"},{"@type":"WebSite","@id":"https:\/\/ctm.ube.fr\/#website","url":"https:\/\/ctm.ube.fr\/","name":"CTM","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/ctm.ube.fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"CTM -","og:type":"article","og:title":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial - CTM","og:description":"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with","og:url":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/","og:image":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg","og:image:secure_url":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg","article:published_time":"2023-08-10T17:50:33+00:00","article:modified_time":"2024-01-26T18:00:37+00:00","twitter:card":"summary_large_image","twitter:title":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial - CTM","twitter:description":"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derang\u00e8re V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with","twitter:image":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg"},"aioseo_meta_data":{"post_id":"4915","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2024-01-26 17:57:06","updated":"2025-08-13 19:14:06","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/ctm.ube.fr\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/\" title=\"Publication\">Publication<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tFirst-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/ctm.ube.fr"},{"label":"Publication","link":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/"},{"label":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial","link":"https:\/\/ctm.ube.fr\/index.php\/2023\/08\/10\/first-line-durvalumab-and-tremelimumab-with-chemotherapy-in-ras-mutated-metastatic-colorectal-cancer-a-phase-1b-2-trial\/"}],"publishpress_future_action":{"enabled":false,"date":"2026-07-29 11:04:26","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts\/4915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/comments?post=4915"}],"version-history":[{"count":2,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts\/4915\/revisions"}],"predecessor-version":[{"id":4919,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts\/4915\/revisions\/4919"}],"wp:attachment":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/media?parent=4915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/categories?post=4915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/tags?post=4915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}